Cardiovascular Systems, Inc.

286 articles with Cardiovascular Systems, Inc.

• Cardiovascular Systems, Inc. Reports Fiscal 2022 Third Quarter Financial Results

  5/4/2022

  Cardiovascular Systems, Inc. today reported financial results for its third quarter, ended March 31, 2022.

• Cardiovascular Systems, Inc. to Host Earnings Conference Call on May 4, 2022

  4/13/2022

  Cardiovascular Systems, Inc. plans to announce its operating results for the quarter ended March 31, 2022 before the market opens on Wednesday, May 4, 2022, and will host a conference call at 8:00 a.m. CT that day to discuss those results.

• Cardiovascular Systems, Inc. to Participate at Two Upcoming Healthcare Conferences

  3/22/2022

  Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host investor meetings at two upcoming healthcare conferences.

• Cardiovascular Systems, Inc. Announces First In-Human Experience With Company’s Propel™ Percutaneous Ventricular Assist Device

  3/16/2022

  Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), announced today the first in-human experience with Propel™, its first-generation percutaneous ventricular assist device (pVAD), offering hemodynamic support for patients undergoing high-risk percutaneous coronary interventions (HR-PCI).

• Cardiovascular Systems, Inc. Announces First In-Human Experience With Peripheral Everolimus Drug-Coated Balloon

  3/9/2022

  Cardiovascular Systems, Inc. announced today the start of enrollment in a first in-human trial of the peripheral everolimus drug-coated balloon (DCB) being developed by Chansu Vascular Technologies, LLC (CVT).

• Cardiovascular Systems, Inc. Appoints Jeffery W. Chambers, M.D., as Chief Medical Officer

  3/4/2022

  Cardiovascular Systems, Inc. today announced that it has appointed Jeffery W. Chambers, M.D., as Chief Medical Officer.

• Cardiovascular Systems, Inc. Announces Partnership With Innova Vascular, Inc. to Develop Full Line of Thrombectomy Devices

  2/23/2022

  Cardiovascular Systems, Inc. announced today it has partnered with Innova Vascular, Inc.

• Cardiovascular Systems, Inc. Reports Fiscal 2022 Second Quarter Financial Results

  2/3/2022

  Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, reported financial results for its second quarter, ended December 31, 2021.

• Cardiovascular Systems, Inc. to Participate at SVB Leerink 2022 Global Healthcare Conference

  1/27/2022

  Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host investor meetings at the SVB Leerink 2022 Global Healthcare Conference.

• Cardiovascular Systems, Inc. and OrbusNeich Announce FDA PMA Approval of Scoreflex® Scoring Balloon

  1/20/2022

  Cardiovascular Systems, Inc. and OrbusNeich Announce FDA PMA Approval of Scoreflex ® Scoring Balloon.

• Cardiovascular Systems, Inc. Announces Development of Intravascular Lithotripsy Technology for the Treatment of Coronary and Peripheral Artery Diseases

  1/13/2022

  Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), announced today it has made significant progress towards the commercialization of intravascular lithotripsy (IVL) systems for the treatment of calcific coronary and peripheral artery disease.

• Cardiovascular Systems, Inc. to Webcast Fiscal 2022 Second-Quarter Earnings Conference Call Thursday, February 3

  1/6/2022

  Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII) will host a live webcast of its fiscal 2022 second-quarter conference call on Thursday, February 3, 2022, at 8:00 a.m. CT (9:00 a.m. ET).

• Cardiovascular Systems, Inc. Initiates Voluntary Recall of WIRION® Embolic Protection System

  11/24/2021

  Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) has initiated a voluntary recall of unused WIRION Embolic Protection Systems (WIRION) due to complaints of filter breakage during retrieval.

• Cardiovascular Systems, Inc. Reports Fiscal 2022 First Quarter Financial Results

  11/9/2021

  Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, reported financial results for its fiscal first quarter, ended September 30, 2021.

• Cardiovascular Systems, Inc. Announces First In-Human Experience With Coronary Everolimus Drug Coated Balloon

  11/4/2021

  Cardiovascular Systems, Inc. announced today the start of enrollment in a first in-human trial of the coronary everolimus drug-coated balloon (DCB) being developed by Chansu Vascular Technologies, LLC (CVT).

• Cardiovascular Systems, Inc. to Participate at the Stifel 2021 Virtual Healthcare Conference

  11/2/2021

  Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), today announced that management plans to present and host investor meetings at the Stifel 2021 Virtual Healthcare Conference.

• Cardiovascular Systems, Inc. to Webcast Fiscal 2022 First-Quarter Earnings Conference Call Tuesday, November 9

  10/11/2021

  Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will host a live webcast of its fiscal 2022 first-quarter conference call on Tuesday, November 9, 2021, at 8:00 a.m. CT (9:00 a.m. ET).

• Cardiovascular Systems, Inc. Announces First Patient Treated with ViperCross™ Peripheral Support Catheter

  9/29/2021

  Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patient has been successfully treated with its ViperCross peripheral support catheter.

• First Patients in Canada Treated With Cardiovascular Systems, Inc. Diamondback 360® Coronary Orbital Atherectomy System

  8/30/2021

  Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patients in Canada have been treated with its Diamondback 360® Coronary Orbital Atherectomy System (OAS).

• Cardiovascular Systems, Inc. Reports Fiscal 2021 Fourth Quarter and Full Year Financial Results

  8/4/2021

  Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its fiscal fourth quarter, ended June 30, 2021.